What are the diagnostic criteria for smoldering multiple myeloma?

Diagnostic Criteria for Smoldering Multiple Myeloma

Smoldering multiple myeloma requires both a serum monoclonal protein (IgG or IgA) ≥3 g/dL and/or clonal bone marrow plasma cells ≥10%, with the critical absence of any end-organ damage (CRAB criteria) or myeloma-defining biomarkers. 1, 2

Core Diagnostic Requirements

Both of the following criteria must be met for SMM diagnosis:

• Serum monoclonal protein ≥3 g/dL and/or clonal bone marrow plasma cells ≥10% 3, 1, 2
• Complete absence of end-organ damage attributable to the plasma cell disorder 1, 2

The monoclonal protein must be of IgG or IgA subtype (not IgM), and plasma cells must be confirmed as clonal 3. This distinguishes SMM from MGUS, which requires serum monoclonal protein <3 g/dL and clonal bone marrow plasma cells <10% 2.

Essential Diagnostic Testing

Laboratory Evaluation

Perform the following tests to establish the diagnosis:

• Serum protein electrophoresis with immunofixation to detect and characterize the M-protein 4, 2
• 24-hour urine protein electrophoresis with immunofixation (not random urine) to quantify urinary M-protein 2
• Serum free light-chain assay with involved/uninvolved ratio for additional prognostic information 1, 2
• Nephelometric quantification of IgG, IgA, and IgM for immunoglobulin profiling 4, 2
• Complete blood count with differential to exclude anemia (hemoglobin must be >10 g/dL or within 2 g/dL of normal) 2
• Serum creatinine and calculated creatinine clearance to exclude renal insufficiency (must be <2 mg/dL or creatinine clearance >40 mL/min) 2
• Serum calcium to exclude hypercalcemia (must be ≤11.5 mg/dL) 2

Bone Marrow Assessment

• Bone marrow aspiration and/or biopsy is mandatory to quantify clonal plasma cells (≥10% threshold) 4, 2
• Cytogenetic studies with FISH should be performed on all marrow samples to identify high-risk abnormalities (del(17p), t(4;14), t(14;16), gain 1q) for risk stratification 2

Imaging Studies

• Skeletal radiographic survey (spine, pelvis, skull, humeri, femurs) is required to exclude lytic bone lesions 4, 2
• MRI of spine and pelvis is recommended at baseline because it can detect occult lesions and predict more rapid progression to symptomatic myeloma 1
• CT or MRI of symptomatic sites should be performed even if skeletal survey is negative when clinical symptoms suggest bone involvement 4, 2

Exclusion of CRAB Criteria

SMM diagnosis requires the complete absence of the following myeloma-defining features:

• Hypercalcemia: serum calcium must be ≤11.5 mg/dL 2
• Renal insufficiency: creatinine must be <2 mg/dL or creatinine clearance >40 mL/min 2
• Anemia: hemoglobin must be within 2 g/dL of the lower limit of normal or >10 g/dL 2
• Bone lesions: no lytic lesions, severe osteopenia, or pathologic fractures on imaging 2

Exclusion of Myeloma-Defining Biomarkers

The following biomarkers, if present, would reclassify the patient as having symptomatic multiple myeloma rather than SMM:

• Bone marrow plasma cells ≥60% 5
• Serum involved/uninvolved free light-chain ratio ≥100 (with involved FLC ≥100 mg/L) 5
• More than one focal lesion ≥5 mm on MRI 5

Risk Stratification After Diagnosis

Once SMM is diagnosed, risk stratification identifies patients at highest risk of progression:

• High-risk SMM is defined by the presence of all three factors: abnormal FLC ratio, bone marrow plasma cells ≥10%, and serum M-protein ≥3 g/dL, with a 5-year progression rate of 76% 1
• Intermediate-risk patients with 2 risk factors have a 51% 5-year progression rate 1
• Low-risk patients with 1 risk factor have a 25% 5-year progression rate 1

The Mayo 20/2/20 criteria (M-protein ≥2 g/dL, involved/uninvolved FLC ratio ≥20, bone marrow plasma cells ≥20%) further refine high-risk identification 6.

Follow-Up Monitoring

After establishing SMM diagnosis:

• Repeat serum protein electrophoresis, complete blood count, calcium, and creatinine 2-3 months after initial diagnosis 1
• If stable, repeat studies every 4-6 months for the first year 1
• If still stable, extend monitoring to every 6-12 months thereafter 1
• Repeat skeletal survey only if there is evidence of progression in routine studies 1

Critical Diagnostic Pitfalls

• Never use random urine samples for M-protein quantification; a properly collected 24-hour urine is mandatory 2
• Always perform immunofixation even when electrophoresis shows no visible peak to avoid missing light-chain-only disease 2
• Do not rely on serum FLC assay alone to replace 24-hour urine protein electrophoresis in patients with measurable urinary M-protein 2
• Obtain FISH studies on all bone marrow samples because high-risk cytogenetic features fundamentally alter prognosis and may influence treatment decisions 2
• Consider advanced imaging (MRI/CT) even with a negative skeletal survey if clinical symptoms suggest bone involvement 2